Basilea Pharmaceutica AG (BPMUF.OB) has sought FDA approval for its antibiotic Ceftobiprole and a decision is due on April 3, 2024.Ceftobiprole is proposed for three indications in the U.S. - staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia.The drug is currently approved and sold under the names Zevtera and Mabelio in various European countries and other regions for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP), excluding ventilator-associated bacterial pneumonia (VABP), and for the treatment of community-acquired bacterial pneumonia (CABP). BPMUF.OB is currently (Mar.28, 2024) trading at $40.75.